The association between quality care and outcomes for a real-world population of Australian patients diagnosed with pancreatic cancer

Maharaj, AD; Evans, SM; Ioannou, LJ; Croagh, D; Earnest, A; Holland, JF; Pilgrim, CHC; Neale, RE; Goldstein, D; Kench, JG; Merrett, ND; White, K; Burmeister, EA; Evans, PM; Hayes, TM; Houli, N; Knowles, B; Leong, T; Nikfarjam, M; Philip, J; Quinn, M; Shapiro, J; Smith, MD; Spillane, JB; Wong, R; Zalcberg, JR

Author(s): Maharaj, AD; Evans, SM; Ioannou, LJ; Croagh, D; Earnest, A; Holland, JF; Pilgrim, CHC; Neale, RE; Goldstein, D; Kench, JG; Merrett, ND; White, K; Burmeister, EA; Evans, PM; Hayes, TM; Houli, N; Knowles, B; Leong, T; Nikfarjam, M; Philip, J; Quinn, M; Shapiro, J; Smith, MD; Spillane, JB; Wong, R; Zalcberg, JR;
Details: Publication Year 2022-06,Volume 24,Issue #6,Page 950-962
Journal Title: HPB
Publication Type: Research article
Abstract: BACKGROUND: This study: (i) assessed compliance with a consensus set of quality indicators (QIs) in pancreatic cancer (PC); and (ii) evaluated the association between compliance with these QIs and survival. METHODS: Four years of data were collected for patients diagnosed with PC. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). A multivariable analysis tested the relationship between significant patient and hospital characteristics, patient cluster effects within hospitals and survival. RESULTS: 1061 patients were eligible for this study. Significant association with improved survival were: (i) in the potentially resectable group having adjuvant chemotherapy administered following surgery or a reason documented (HR, 0.29; 95 CI, 0.19-0.46); (ii) in the locally advanced group included having chemotherapy +/- chemoradiation, or a reason documented for not undergoing treatment (HR, 0.38; 95 CI, 0.25-0.58); and (iii) in the metastatic disease group included having documented performance status at presentation (HR, 0.65; 95 CI, 0.47-0.89), being seen by an oncologist in the absence of treatment (HR, 0.48; 95 CI, 0.31-0.77), and disease management discussed at a multidisciplinary team meeting (HR, 0.79; 95 CI, 0.64-0.96). CONCLUSION: Capture of a concise data set has enabled quality of care to be assessed.
Keywords: Australia/epidemiology; Chemotherapy, Adjuvant; Humans; *Pancreatic Neoplasms; Proportional Hazards Models
Department(s): Radiation Oncology; Surgical Oncology
PubMed ID: 34852933
Publisher's Version: https://doi.org/10.1016/j.hpb.2021.11.005
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-01-31 03:38:47

Last Modified: 2025-01-31 03:40:50